Platform|API|Archive|Contact

Humanexa SignalsPharmaceutical Intelligence

FDA
EMA
MHRA
PMDA
Health Canada

Phase I
Phase II
Phase III
Readouts
Enrollment Signals

Pipeline Tracking
Company Moves
Asset Intelligence
Landscape Reports

Pricing
Access
Commercial
Launch Tracking

Licensing
Acquisitions
Partnerships
Capital Raises

Strategy Catalysts Pricing

Humanexa Signals

Data-driven pharmaceutical intelligence for biotech investors, pharma operators, consultants, and intelligence teams.

Powered by Humanexa

Categories

Regulatory
Clinical
Competitive
Markets
M&A Watch
Strategy
Catalyst Tracker

Company

Pricing
Partner with us
Subscribe
Contact
Privacy

Subscribe to Humanexa Signals

Weekly intelligence for pharma decision-makers.

No paywall. No spam. Unsubscribe anytime.

© 2026 Humanexa Signals. All rights reserved.

Intelligence powered by the Humanexa engine.

Asset / Drug

Scotiaderm

Drug and asset intelligence for Scotiaderm with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals: 1
Catalysts: 1
Stage: Development stage unavailable

Recent signals(1)

ClinicalJune 29, 2026

Scotiaderm Initiates Trial for Novel Barrier Cream Against Moisture Associated Skin Damage

Scotiaderm is conducting a clinical trial to evaluate the efficacy of its Dermategrity 'Anti-fecal' Barrier Cream against standard zinc oxide creams for treating moisture-associated skin damage.

Upcoming milestones

No catalysts indexed for this entity yet.

Related catalysts(1)

Topline Data

— Scotiaderm

Monitor trial results and any announcements regarding the efficacy of Dermategrity compared to existing treatments.

June 29, 2026 · N/A

Indications

No related entities indexed yet.

Therapeutic areas

Dermatology →

Dermatology · Skin Damage →

Skin Damage →

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.